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Background: In the absence of accessible, good quality eye health services and inclusive environments, vision loss
can impact individuals, households and communities in many ways, including through increased poverty,
reduced quality of life and reduced employment. We aimed to estimate the annual potential productivity losses
associated with reduced employment due to blindness and moderate and severe vision impairment (MSVI) at a
regional and global level.
Methods: We constructed a model using the most recent economic, demographic (2018) and prevalence
(2020) data. Calculations were limited to the working age population (1564 years) and presented in 2018
US Dollars purchasing power parity (ppp). Two separate models, using Gross Domestic Product (GDP) and
Gross National Income (GNI), were calculated to maximise comparability with previous estimates.
Findings: We found that 160.7 million people with MSVI or blindness were within the working age and esti-
mated that the overall relative reduction in employment by people with vision loss was 30.2%. Globally, using
GDP we estimated that the annual cost of potential productivity losses of MSVI and blindness was $410.7 bil-
lion ppp (range $322.1 - $518.7 billion), or 0.3% of GDP. Using GNI, overall productivity losses were estimated
at $408.5 billion ppp (range $320.4 - $515.9 billion), 0.5% lower than estimates using GDP.
Interpretation: These findings support the view that blindness and MSVI are associated with a large economic
impact worldwide. Reducing and preventing vision loss and developing and implementing strategies to help
visually impaired people to find and keep employment may result in significant productivity gains
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Global Eye Health was supported by grants from The Queen Elizabeth Diamond Jubilee Trust, Moorfields Eye
Charity (GR001061), NIHR Moorfields Biomedical Research Centre, The Wellcome Trust, Sightsavers, The Fred
Hollows Foundation, The SEVA Foundation, The British Council for the Prevention of Blindness and Christian Blind
Mission. The funders had no role in the design, conduct, data analysis of the study, or writing of the manuscript.
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Research in context
Evidence before this study:
We conducted a systematic review to describe and summarize
the costs associated with vision impairment and its major
causes at a global level (reported elsewhere). In brief, a litera-
ture search (20002019) with no geographic or language
restrictions was performed in MEDLINE (Ovid) and the CRD
database (Centre for Reviews and Dissemination) in December
2019. Only three studies reported productivity loss estimates at
a global or multi-region level for blindness and vision
impairment. The widespread use of assumptions to produce
productivity loss estimates in many studies highlighted the
lack of reliable and up-to-date data sources for most regions.
These older estimates, based on outdated data, less robust
information for parameters, and little assessment of uncer-
tainty, have limitations in terms of reliability and current
applicability.
Added value of this study:
As part of the Lancet Global Health Commission on Global Eye
Health, this economic modelling study uses the most recent
economic, demographic and prevalence data on moderate and
severe vision impairment (MSVI) and blindness to estimate the
annual cost of potential productivity losses due to unaddressed
blindness and MSVI globally and for each Global Burden of Dis-
ease (GBD) region. Further, we based our estimates of the rela-
tive reduction in employment due to vision loss on a literature
review, instead of following the assumptions made in previous
studies. We estimated that the annual global cost in potential
productivity losses due to blindness and MSVI was approxi-
mately $410.7 billion ppp (range $322.1 to $518.7 billion) in
2018.
Implications of all the available evidence:
Our findings support the view that blindness and MSVI are
associated with a large economic impact worldwide. All regions
of the world could achieve significant productivity gains if eye
health services were more accessible, and included prevention
and treatment of vision loss as well as comprehensive rehabili-
tation services. It is also critical to implement strategies to
enable visually impaired people to find and keep employment,
and create more accessible and inclusive cultures and environ-
ments for people with vision loss.
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Worldwide in 2020 an estimated 596.2 million people have dis-
tance vision impairment, of whom 43.3 million are blind and
295.1 million have moderate or severe vision impairment (MSVI) [1].
A further 509.7 million have uncorrected near vision impairment.
Vision impairment and impaired eye health can have a wide-reaching
and major impact on the lives of individuals, their families and soci-
ety [2]. Vision impairment can cause or exacerbate poverty through
reduced employment prospects and work productivity [3-6], as well
as adversely affect educational opportunities and outcomes [7].
Impaired vision and eye health can also impact general health and
well-being, with associated reductions in quality of life [8]. Therefore,
eye health can be considered a broad-based development issue.
Addressing population eye health and vision impairment has the
potential to be a powerful enabler for achieving the Sustainable
Development Goals (SDGs) [9,10]Economic productivity at the individual, family and national level
is critically important to sustainable development. From an economic
perspective, the productive capacity of the economy is reduced when
labour input (workforce) decreases through people being unem-
ployed or underemployed. This is quantified by estimating productiv-
ity losses [11]. Illness and disability can contribute to productivity
losses through one or more of: (1) an absence from work (absentee-
ism), (2) a reduction in production while at work (presenteeism), or
(3) a reduction in employment including job loss and early retire-
ment.
To build a more complete picture of the individual and societal
impact of vision impairment, it is necessary to understand the extent
of the associated attributable economic productivity losses. Combin-
ing this with other sources of evidence about the impact of vision
impairment informs policy makers about the relative importance of
eye health, and the potential costs and benefits of addressing this. As
part of the Lancet Global Health Commission on Global Eye Health
[12], in this study we estimated the annual economic productivity
losses associated with reduced employment due to blindness and
MSVI.
2. Methods
This study modelled the annual cost of productivity losses associ-
ated with reduced employment due to unaddressed blindness and
MSVI globally and for each Global Burden of Disease (GBD) region.
The calculation included: (1) the number of people with blindness or
MSVI of working age (1564 years) in 2020, (2) the employment-to-
population ratio in 2018, (3) the relative reduction in employment
for people with vision loss, and (4) per capita Gross Domestic Product
(GDP) or Gross National Income (GNI) for 2018.
2.1. Prevalence of blindness and MSVI in the working age population
Blindness was defined as presenting distance visual acuity <3/60
in the better eye and MSVI as presenting distance visual acuity (i.e.
with correction if usually worn) of between <6/18 to 3/60 in the bet-
ter eye. As such, monocular blindness or MSVI were not included in
the prevalence data. The working age population was defined as
those aged 15 to 64 years old inclusive [13]. Data on the number of
people of working age with blindness or MSVI (and 95% uncertainty
intervals [UI]) in each GBD region in 2020 were provided by the GBD
Study / Vision Loss Expert Group (VLEG) [1]. RB provided VLEG preva-
lence data in 5-year increments of age; from these data, APM
extracted the working age population data by region. APM and RB
had access to these data for analysis throughout the study period.
2.2. Employment-to-population ratio
We defined employment-to population ratio as the proportion of
a country’s population aged 15 years and over that is employed, in
paid full-time or part-time employment or self-employment either at
work or having a job but in temporary absence (e.g. parental leave,
sick leave, annual leave) [14]. It is generally measured during a speci-
fied brief period, such as one week or one day. We sourced data from
the World Banks World Development Indicator database for 2018, or
the most recent year available (data were unavailable from 11 coun-
tries). [15]. APM collected these data and summarised them at a
regional level (shown in supplementary Table 1).
2.3. Relative reduction in employment for people with vision loss
We estimated the relative reduction in employment by comparing
levels of reported employment levels in people with and without
vision loss. We searched for relevant literature in Medline (OVID) and
Google in February 2020 using the search terms: (employment OR
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OR visual impairment OR blindness OR cataract OR glaucoma OR age-
related macular degeneration OR diabetic retinopathy). We sought
studies or reports from any country published since the year 2000
that reported the employment status of people with vision loss and/
or the employment reduction between people with and without
vision loss.
We identified 11 peer-reviewed published studies [16-26] and
five grey literature reports [27-31] that provided employment reduc-
tion data for 15 countries and WHO Mortality Stratum regions, which
provide estimates for eight GBD regions and three GBD super regions
(supplementary Table 2). Employment reduction was reported using
employment rates or labour force participation rates. Many of these
studies did not report how employment was defined and those which
did used several different definitions (for example self-employment
was not always included). Further, there was a range of definitions
for vision loss and for the working age population. Employment data
on people with vision loss were compared to either people without
vision loss, people without any disability, or with the general popula-
tion. The relative reduction in employment for each region and super
region was calculated as the weighted average employment gap of
the countries that reported data within each region or super region
(with the total population of each country being the weight). Due to
limited data, we could not disaggregate reduction in employment for
blindness compared to MSVI, or for different age groups or separately
for women and men. When estimating productivity losses by GBD
region, we used the GBD super region average whenever there was
no data for a specific region. If there were no data for both a region
and its super region the global average of all super regions was used.
2.4. Gross domestic product (GDP) and gross national income (GNI)
We assumed the annual cost of potential productivity losses asso-
ciated with reduced employment due to MSVI or blindness was equal
to GDP or GNI per capita. GDP is the sum of the gross value added by
all resident producers in the economy[32]. GNI is the sum of value
added by all resident producers plus net receipts of primary income
(compensation of employees and property income) from abroad [33].
We developed both GDP and GNI models to generate results that
could be compared to previous estimates, as both approaches have
been used in the past [16,34,35]. Data were sourced from the World
Banks World Development Indicator database in 2018 US Dollar pur-
chasing power parity (ppp) for 2018, or the most recent year for
which data were available (summarised in supplementary Table 1;
data were unavailable for six countries).
2.5. Estimating the annual cost of economic productivity loss
The annual potential productivity loss associated with reduced
employment was estimated for each region, following an approach
used several times previously[16,36,37] and using the formula:
Annual potential productivity losses region að Þ ¼
Prev: Blindness and MSVI working age population region að Þ X
Employment  to population ratio region að Þ X
Relative Reduction in employment region að Þ X
GDP per capita region að Þ or GNI per capita region að Þ
 
The employment-to-population ratio, GDP per capita ppp and GNI
per capita ppp for each GBD region were calculated as the weighted
average of the data from each country in the region with available
data; the total population of each country was used as the weight
(supplementary appendix) [38]. Similarly, the relative reduction in
employment of people with vision loss for each region or super
region was calculated as the weighted average reduction in employ-
ment for the countries in the region or super region using totalpopulation of each region country as the weight (supplementary
appendix). Productivity losses by region are reported in billion 2018
US Dollars ($) ppp, and as a percentage of GDP ($ ppp) [39]. GDP ppp
per region was calculated as the sum of GDP ppp of the countries
included in each GBD region.
Sensitivity analyses were performed to evaluate whether the
uncertainty of the prevalence data and the relative reduction in
employment data result in substantive changes in the estimates. We
used available published prevalence [1] and relative reduction in
employment data for the sensitivity analysis [40-42]. First, the upper
and lower values of the 95% uncertainty intervals of the number of
people in the working age population with MSVI or blindness were
used to generate a range for each of the productivity loss estimates.
This range is presented with the global estimate and for the estimate
calculated for each region. Second, we substituted the data on rela-
tive reduction in employment derived from the literature search
with data from the Eurostat disability statistics and recalculated all
estimates (supplementary Table 3) [40]. Eurostat disability statistics
reported employment reduction data from 31 countries included in
four regions and three super regions for people reporting disabilities
in basic activities, defined as an ‘activity difficulty such as sight, hear-
ing, walking and communicating’. Third, we substituted the data on
the relative reduction in employment with the disability weights for
blindness and vision impairment published by WHO. [41,42]. By
doing so we used disability weights as a proxy for the extent of lost
productivity assuming a linear relationship between productivity
and disability weights. Disability weights for distance vision
impairment are reported for four levels of severity (mild, moderate,
severe and blindness) which did not align with the categories of
prevalence data in our model (blindness and MSVI). Therefore, MSVI
prevalence data had to be split, and we assumed an equal split
between the moderate and severe categories.
2.6. Role of the funding source
The funders had no role in the study design, data collection, data
analysis, data interpretation, writing of the manuscript, or in the
decision to submit the manuscript for publication. This modelling
study used published or publicly available data. APM and TB had full
access to all the data in the study and all authors accept responsibility
to submit for publication.
3. Results
Globally, in 2020, there were an estimated 18.1 million (95%UI
14.4 million - 22.6 million) people in the working age population
who were blind and 142.6 million (95%UI 112.5 million - 179.5 mil-
lion) who had MSVI. These people represent 41.9% and 48.3% of all
people with blindness and MSVI, and 0.4% and 2.4% of the global
working age population, respectively. The numbers of people affected
in each region are presented in Table 1. The global average relative
reduction in employment of people with vision impairment or blind-
ness was estimated to be 30.2%. The available regional or super
regional values are presented in Table 2.
Using GDP, we estimated the annual cost of potential productivity
losses in 2018 was $410.7 billion ppp (range $322.1 billion to $518.7
billion ppp), of which $43.6 billion ppp (range $34.4 billion to $54.5
billion ppp) was due to blindness and $367.1 billion ppp (range
$287.7 billion to $464.2billion ppp) was due to MSVI. This overall pro-
ductivity loss amount represented 0.3% of the combined GDP of the
21 GBD regions in 2018. The regional estimates are presented in
Table 3 and Fig. 1. East Asia (comprised of China and North Korea)
was the region with the highest productivity loss estimates ($90.4
billion ppp; range $70.5 billion to $115.3 billion ppp) and Oceania the
lowest ($0.2 billion ppp; range $0.1 billion to $0.2 billion ppp). Half
(51%) of all global productivity losses were concentrated in three
Table 1
Blindness or moderate to severe vision impairment in the working age population (1564 years) in the 21 Global Burden of Disease Study regions in 2020.









% Total MSVI (95%UI) % Working age
population (95% UI)
High-income Asia Pacific 0.17 (0.140.21) 31.6% (31.4%31.7%) 0.1% (0.1%0.2%) 1.82 (1.422.30) 34.1% (33.4%34.5%) 1.5% (1.2% 2.0%)
Australasia 0.02 (0.020.03) 32.5% (32.0%32.9%) 0.1% (0.1%0.1%) 0.3 (0.240.39) 40.3% (39.9%40.7%) 1.6% (1.2% 2.0%)
Western Europe 0.40 (0.310.51) 26.4% (26.1%26.8%) 0.1% (0.1%0.2%) 5.94 (4.627.52) 38.5% (37.9%39.1%) 2.1% (1.7% 2.7%)
Southern Latin America 0.06 (0.050.08) 37.9% (37.7%38.4%) 0.1% (0.1%0.2%) 1.02 (0.791.29) 48.1% (47.5%48.6%) 2.3% (1.8%3.0%)
High-income North America 0.23 (0.180.29) 32.4% (32.1%32.7%) 0.1% (0.1%0.1%) 3.26 (2.544.11) 43.8% (43.2%44.2%) 1.4% (1.2% 1.7%)
Central Asia 0.16 (0.120.21) 52.4% (52.4%52.8%) 0.3% (0.2%0.3%) 1.66 (0.302.10) 56.1% (55.6%56.8%) 2.7% (2.1%3.5%)
Central Europe 0.11 (0.090.14) 34.2% (34.1%34.3%) 0.2% (0.1%0.2%) 1.45 (1.121.87) 36.7% (36.1%37.4%) 1.9% (1.5%2.5%)
Eastern Europe 0.26 (0.210.33) 33.6% (33.4%33.7%) 0.2% (0.2%0.2%) 4.74 (3.696.06) 42.8% (42.0%43.6%) 3.4% (2.6%4.3%)
Caribbean 0.11 (0.080.14) 40.6% (40.5%40.9%) 0.4% (0.3%0.5%) 0.78 (0.610.99) 50.5% (49.8%51.1%) 2.8% (2.1%3.5%)
Andean Latin America 0.13 (0.100.17) 37.5% (37.4%37.9%) 0.3% (0.3%0.4%) 1.42 (0.101.79) 51.4% (50.4%52.0%) 3.6% (2.8%4.6%)
Central Latin America 0.54 (0.420.69) 42.8% (42.7%43.1%) 0.3% (0.3%0.4%) 5.29 (4.106.71) 53.7% (52.9%54.4%) 3.2% (2.5%4.0%)
Tropical Latin America 0.71 (0.570.87) 39.9% (39.8%40.1%) 0.5% (0.4%0.6%) 5.83 (4.547.34) 56.4% (55.7%56.9%) 3.9% (3.0%4.9%)
North Africa and Middle East 1.30 (0.991.71) 42.2% (42.0%42.4%) 0.3% (0.3%0.4%) 11.55 (9.1514.44) 52.9% (52.5%53.3%) 3.0% (2.4%3.8%)
South Asia 4.92 (3.876.18) 41.2% (41.1%41.5%) 0.4% (0.3%0.5%) 50.68 (39.8764.1) 52.7% (51.6%53.9%) 4.4% (3.4%5.5%)
Southeast Asia 2.67 (2.123.32) 44.8% (44.7%45.0%) 0.6% (0.5%0.7%) 13.88 (11.3017.01) 48.2% (47.2%49.3%) 3.1% (2.4%3.7%)
East Asia 3.76 (3.024.64) 41.4% (40.9%41.9%) 0.4% (0.3%0.5%) 21.65 (16.827.78) 40.2% (39.4%41.1%) 2.1% (1.7% 2.8%)
Oceania 0.02 (0.020.03) 62.4% (62.3%62.9%) 0.4% (0.3%0.5%) 0.22 (0.170.28) 56.8% (56.2%57.5%) 3.3% (2.6% 4.2%)
Central Sub-Saharan Africa 0.17 (0.120.22) 57.5% (57.4%58.3%) 0.3% (0.2%0.3%) 1.13 (0.881.45) 56.4% (56.0%56.8%) 1.7% (1.3% 2.2%)
Eastern Sub-Saharan Africa 1.03 (0.811.3) 52.3% (52.2%52.4%) 0.5% (0.4%0.6%) 3.81 (3.014.79) 54.4% (53.9%54.8%) 1.8% (1.4% 2.2%)
Southern Sub-Saharan Africa 0.22 (0.180.28) 46.3% (46.2%46.4%) 0.4% (0.4%0.6%) 0.84 (0.651.06) 53.6% (53.1%54.1%) 1.7% (1.3% 2.1%)
Western Sub-Saharan Africa 1.12 (0.881.42) 47.8% (47.8%48.3%) 0.5% (0.4%0.6%) 5.35 (4.226.75) 54.3% (53.7%54.9%) 2.4% (1.9% 3.0%)
Total 18.12 (14.4222.62) 41.9% (41.8%42.1%) 0.4% (0.3%0.5%) 142.62 (112.50179.54) 48.3% (47.6%49.2%) 2.4% (1.9% 3.0%)
Data source: GBD/VLEG 2020 data [1]. Population Working age data [56]. UI: uncertainty interval. % Total Blindness or % Total MSVI was calculated as the quotient between the
number of people with blindness or MSVI in the working age and the number of people with blindness or MSVI in all ages. % Working age population was calculated as the quo-
tient between the number of people with blindness or MSVI in the working age and the working age population.
Table 2
Relative reduction in employment for people with vision loss (%).
GBD Super regions (bold) and
regions
Relative reduction in employment
among people with vision loss (%)
High Income 32.12
High-income Asia Pacific 26.70
Australasia 32.44
Western Europe 20.58
Southern Latin America No data
High-income North America 43.46






Latin America and Caribbean No data
Caribbean No data
Andean Latin America No data
Central Latin America No data
Tropical Latin America No data
North Africa and Middle East No data
South Asia No data
Southeast Asia, East Asia, and
Oceania
No data
Southeast Asia No data
East Asia No data
Oceania No data
Sub-Saharan Africa 28.85
Central Sub-Saharan Africa No data
Eastern Sub-Saharan Africa No data
Southern Sub-Saharan Africa No data
Western Sub-Saharan Africa 28.85
Average 30.23
Number of countries with data 15a
a Relative reduction in employment data was obtained from a literature
search. We identified 11 studies [1626] and 5 reportsce: [2731] that provided
employment reduction data for 15 countries andWHOMortality Stratum regions,
which we categorised into 8 GBD regions and 3 super regions
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marily due to the high number of people with MSVI or blindness in
East Asia and South Asia (50% of all people with vision loss in the
working age population), and the high GDP per capita (supplemen-
tary Table 1), and high relative reduction in employment in High-
income North America (Table 2). Productivity losses due to MSVI and
blindness in South Asia represented 0.6% of the GDP in 2018 in this
region, more than twice the impact found in North America (0.2%
GDP). In contrast, Eastern Sub-Saharan Africa was the region with the
lowest GDP per capita (approximately 4% of High-income North
America) which led to the region accounting for only 0.6% of global
potential productivity losses despite being home to 3% of people in
the working age population with MSVI or blindness and having one
of the highest employment to population ratios (supplementary
Table 1). Productivity losses due to MSVI and blindness represented
0.3% of Eastern Sub-Saharan Africa GDP in 2018.
Using GNI, the overall productivity losses were estimated at
$408.5 billion ppp (range $320.4 billion to $515.9 billion ppp), being
$43.3 billion (range $34.2 billion to $54.1 billion ppp) due to blind-
ness and $365.2 billion ppp (range $286.2 billion to $461.8 billion
ppp) due to MSVI. At the global level, estimates using GNI were 0.5%
lower than estimates using GDP and estimates were lower in 19 of
the 21 GBD regions compared to when GDP was used (Table 3, Fig. 1
and Fig. 2). High-income Asia Pacific estimates had an increase of
$0.3 billion ppp (2% increase compared with GDP estimates), while
Caribbean estimates had a decrease of $0.2 billion ppp (12% reduction
compared with GDP).
Using the Eurostat disability statistics, we estimated a relative
reduction in employment of 19.5% at the global level (supplementary
Table 3) compared to 30.2% used above (Table 2). Correspondingly,
global productivity losses in this sensitivity analysis were 36% lower
using both GDP ($262.6 billion ppp [range $205.8 billion to $331.9
billion ppp]) and GNI ($260.8 billion ppp [range $204.4 billion to
$329.7 billion ppp]), supplementary Table 4. The two regions show-
ing the largest reduction in productivity losses were High-income
North America and North Africa and Middle East. Using disability
weights as a proxy for productivity losses, we estimated a reduction
in employment of 33.8% for blindness, 31.4% for severe VI and 8.9%
for moderate VI. At the global level, estimates using disability weights
reached $49.4 billion ppp (range $39.0 billion to $61.8 billion ppp)
Table 3
Economic productivity losses by GBD region (US$ billion ppp, 2018).
GBD regions GDP GNI
Productivity Losses in US$ billion
ppp (95%UI)
Productivity Losses in % GDP
(95%UI)
Productivity Losses in US$ billion
ppp (95%UI)
Productivity Losses in % GDP
(95%UI)
High-income Asia Pacific 13.96 (10.917.62) 0.17 (0.140.22) 14.24 (11.1217.97) 0.18 (0.140.22)
Australasia 3.28 (2.554.18) 0.22 (0.170.28) 3.18 (2.474.05) 0.21 (0.170.27)
Western Europe 33.34 (25.9442.18) 0.16 (0.120.2) 33.53 (26.0942.42) 0.16 (0.120.2)
Southern Latin America 4.27 (3.315.41) 0.27 (0.210.34) 4.10 (3.185.2) 0.26 (0.20.33)
High-income North America 55.51 (43.3370) 0.25 (0.190.31) 56.19 (43.8670.86) 0.25 (0.20.32)
Central Asia 3.33 (2.594.25) 0.29 (0.230.37) 3.15 (2.454.01) 0.28 (0.220.35)
Central Europe 5.37 (4.146.92) 0.16 (0.130.21) 5.18 (46.68) 0.16 (0.120.2)
Eastern Europe 14.54 (11.3318.56) 0.28 (0.220.36) 14.18 (11.0518.1) 0.27 (0.210.35)
Caribbean 1.59 (1.232.02) 0.36 (0.280.46) 1.39 (1.081.77) 0.32 (0.250.4)
Andean Latin America 4.12 (3.185.23) 0.57 (0.440.73) 3.95 (3.055.02) 0.55 (0.420.7)
Central Latin America 17.75 (13.7722.51) 0.41 (0.320.52) 17.26 (13.3921.88) 0.4 (0.310.5)
Tropical Latin America 17.83 (13.9522.4) 0.55 (0.430.7) 17.55 (13.7322.05) 0.54 (0.430.68)
North Africa and Middle East 33.56 (26.4642.17) 0.35 (0.280.44) 33.48 (26.4142.07) 0.35 (0.270.44)
South Asia 61.87 (48.6878.22) 0.57 (0.450.72) 61.78 (48.6178.11) 0.57 (0.450.72)
Southeast Asia 40.17 (32.5749.33) 0.52 (0.420.64) 39.75 (32.2348.82) 0.52 (0.420.63)
East Asia 90.39 (70.47115.31) 0.42 (0.320.53) 90.06 (70.21114.9) 0.41 (0.320.53)
Oceania 0.17 (0.130.21) 0.31 (0.240.39) 0.16 (0.130.21) 0.30 (0.230.38)
Central Sub-Saharan Africa 0.70 (0.540.9) 0.18 (0.140.23) 0.66 (0.510.85) 0.17 (0.130.22)
Eastern Sub-Saharan Africa 2.51 (1.973.15) 0.28 (0.220.35) 2.46 (1.943.1) 0.27 (0.210.34)
Southern Sub-Saharan Africa 1.71 (1.342.16) 0.20 (0.150.25) 1.66 (1.32.1) 0.19 (0.150.24)
Western Sub-Saharan Africa 4.75 (3.745.99) 0.27 (0.210.34) 4.56 (3.595.75) 0.26 (0.210.33)
Total 410.70 (322.13 518.74) 0.32 (0.250.41) 408.47 (320.38 515.91) 0.32 (0.250.41)
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billion ppp) due to severe VI and $55.2 billion ppp (range $43.3 billion
to $69.8 billion ppp) due to moderate VI. The total productivity losses
using disability weights were 27% lower compared to our main esti-
mates when using GDP ($299.4 billion ppp [range $234.9 billion to
$378.0 billion ppp]) and GNI ($297.5 billion ppp [range $233.4 billion
to $375.7 billion ppp]).
4. Discussion
In 2020, 160.7 million people in the working age population were
either blind or had MSVI, representing 3.3% of the global working age
population. We combined these new MSVI and blindness prevalence
data with updated employment gap and economic data, estimating
the annual global productivity losses due to blindness and MSVI at
$410.7 billion ppp (2018), or 0.3% of GDP in 2018. Our global estimate
using GNI was very similar ($408.5 billion ppp), suggesting the esti-
mates are not sensitive to differences between GDP and GNI at the
global level.
We found limited data on the relative reduction in employment of
people with vision loss, with a complete absence of data from some
regions (table 2). However, our global estimate of 30.2% employment
reduction is similar to a population-based survey conducted in 70
countries which reported that 21% of people of working age with
‘severe visual difficulties’ and 36% of people with ‘extreme visual dif-
ficulty’, who wanted to work, were not working [43]. As these data
were not reported by country or region we were unable to include
them in our model.
Previous studies have presented global and multi-country esti-
mates of productivity loss, either for a specific group of regions or
countries, or exclusively for blindness or specific eye conditions, such
as refractive error or trachoma. One estimate of annual global pro-
ductivity loss due to blindness was $26.8 billion ppp when we con-
verted to 2018 $US ppp (supplementary Table 5) [34]. This amount is
much lower than our estimate, largely because it did not include
MSVI, but also because the probability of employment without vision
loss was calculated as the product of the labour force participation
rate and the unemployment rate, greatly reducing the number of
people considered employable. A study that used a methodology sim-
ilar to ours reported productivity losses for the WHO Regions ofAmerica A, Europe A, B1, B2 and C and West Pacific A1 and A2 of
$193.3 billion ppp (when converted to 2018 $US ppp) [16]. These
regions of mostly high-income countries roughly align with the
regions in our study, High-income North America, Western Europe,
Eastern Europe, Central Europe, Central Asia, Australasia and High-
income Asia Pacific, for which we estimated losses of $129 billion
ppp (GDP model).
Our GNI result ( $408.5 billion ppp) aligns with a recent global
study that also used GNI, which estimated global productivity losses
due to blindness and MSVI of $381 billion ppp, (converted to 2018
$US ppp) [35]. Compared to these two studies[16,35] that used simi-
lar methods, we drew on more extensive regional prevalence data
which may have led to some of the difference in the estimates. Other
reasons are that we assumed a more conservative employment gap,
did not include premature mortality in our estimates, [16] and did
not account for reduced wages [35] (more details provided in supple-
mentary Table 5).
Sensitivity analysis demonstrated that our estimates were sensi-
tive to changes in both prevalence and relative reduction in employ-
ment due to vision loss parameters. First, at a global level estimates
varied from $322.1 billion to $518.7 billion (GDP model) when we
used the upper and lower 95% uncertainty intervals of the crude
prevalence of blindness and MSVI. Despite this uncertainty, these
prevalence data are the most accurate and up-to-date information
available [1]. The second sensitivity analysis used Eurostat disability
data for the relative reduction in employment and found productivity
losses to be 36% lower if relative reduction in employment due to
vision loss is assumed to be equal to any other disability such as hear-
ing, walking and communicating. There are examples, such as in Can-
ada, where people with blindness had lower employment rates than
people with any other disability [44]. However, this may reflect that
employment rates vary according to the severity of disability, with
people with more severe disability more likely to be out of the labour
market [45,46,47]. We recognise that better data are needed for rela-
tive reduction in employment for people with vision loss, and believe
that the data we used are more reliable than data for people with any
disability. The third sensitivity analysis used disability weights
reported by WHO as a proxy for relative reduction in employment
and the subsequent productivity losses estimate decreased 27%. We
believe these estimates should be interpreted with caution. These
Fig. 1. Productivity loss estimates using Gross Domestic Product (GDP) due to blindness and MSVI in the 21 Global Burden of Disease regions in 2018 (A) in billion US$ ppp (B) as a
percentage of GDP.
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distributed across each of the moderate and severe VI categories. This
assumption introduced additional uncertainty due to the lack of
references to support this option. We also eliminated regional differ-
ences by applying the same disability weight for the 21 GBD regions
regardless of development level. We used WHO disability weights
instead of GBD disability weights [48] mainly because WHO method-
ology to calculate disability weights included multiple domains of
health, functions, capacities and aspects of living [41]. The use of dis-
ability weights to estimate productivity losses has been considered
less appropriate since a variety of health conditions have almost the
same disability weight even if they may result in differing degrees of
productivity losses [49]. Furthermore, GBD disability weights were
based on a discrete choice comparisons of sequalae in terms of “who
is healthier”, which may not sufficiently capture the impact of blind-
ness and VI on everyday life, because even though blindness is highly
undesirable, blind people are generally not considered sick or ill [41].The strengths of this study include the development and use of a
relatively simple formula to estimate potential productivity losses
that can be easily replicated by countries and non-governmental
organizations to evaluate the case for investing in interventions that
increase employment opportunities for visually impaired individuals.
Our estimates were based on the latest available data and used both
GDP per capita and GNI per capita to enable comparability with pre-
vious estimates. These publicly available data are updated annually
and are internationally standardized which increases the reliability
of our estimates. We based our estimates of the relative reduction in
employment due to vision loss on a literature review instead of fol-
lowing the assumptions made in previous studies such as assuming
productivity losses being equal to disability weights[49-51] or
assuming that a minimum of 70% of people with blindness and 30%
of people with MSVI are not in paid employment [36,37].
Our analysis has several limitations. First, we were only able to
find reports from 15 countries on which to base our estimates of the
Fig. 2. Productivity loss estimates due to blindness and MSVI derived from Gross National Income (GNI) in the 21 Global Burden of Disease regions in 2018 (A) in billion USD ppp, (B)
as a percentage of GDP.
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and the severity of vision loss was rarely reported (Table 2). More-
over, prevalence data were available to us at the regional rather than
country level. This lack of quality data from different countries, for
different levels of severity, different age groups or by sex may
increase uncertainty in our results. We performed a sensitivity analy-
sis to study the impact of different data sources regarding the relative
reduction in employment by using Eurostat statistics that include a
wider range of countries and by estimating potential productivity
losses separately for blindness and MSVI using disability weights.
Estimates decreased in both sensitivity analyses, but more assump-
tions were necessary and therefore more uncertainty was introduced
in both approaches compared to our primary estimate. Although we
explored data insufficiency comprehensively, it is difficult to predict
in what direction this data sparsity has affected the accuracy of our
estimates either by overestimating or underestimating the productiv-
ity losses due to blindness and MSVI.
Second, there are several productivity loss components that we
did not include in our estimates, such as those resulting frompremature mortality, [16] absenteeism and presenteeism (reduced
productivity in the work place), productivity losses of caregivers
[52,53]. We also recognise that we have not included the productivity
losses related to unpaid or informal labour activities. Our reason for
not including these additional components such as, absenteeism, pre-
senteeism and productivity losses of caregivers in our estimates is
that reliable international data are currently lacking. We believe that
excluding these elements is likely to have resulted in an underesti-
mate of the overall magnitude of productivity losses due to blindness
and MSVI.
Third, our estimates were limited to people under 65 years while
other studies have assumed that the working age extends beyond
64 years [18]. Employment in people aged 65 years and older is
largely influenced by the social protection and retirement pension
systems in place at a national level, which vary greatly. For example,
Western European countries generally have more favourable pension
coverage and conditions than other countries and therefore people
feel more secure to retire, with 8% of people aged 6569 years
remaining in paid employment [54]. In contrast, in Sub-Saharan
8 A.P. Marques et al. / EClinicalMedicine 35 (2021) 100852Africa 39% of people in this age group continue to work, [54] perhaps
because they feel less financially secure to retire. The relatively low
employment participation rate among people aged 65 to 69 years in
several regions means that a high proportion of the 39 million people
in this age group who have MSVI or blindness are not employed (sup-
plementary Table 6). We found a single report from Australia which
reported a relative reduction in employment due to vision loss of
4.5% amongst people aged 65 years or older [18]. We recognise these
data are limited, but had we included this age group in our model,
our primary estimate of $410.7 billion ppp would not have been sub-
stantially different (i.e. 1.4% higher).
To improve future estimates of productivity losses, we need more
studies reporting the employment status of people living with blind-
ness and MSVI, particularly in low- and middle-income countries.
Future research should investigate how different severity levels of
vision impairment affect productivity losses and if there are relevant
differences by gender, since traditionally women face more barriers
finding and retaining employment [55]. Employment distribution by
sector of activity and level of education are also important to charac-
terize access, enablers and barriers to paid employment. Longitudinal
studies rather than cross-sectional studies would increase our knowl-
edge about changes of employment status over the course of an eye
condition and identify possible baseline predictors of employment
participation. These could be used in future models to improve pro-
ductivity losses estimates in countries where only a few predictor
variables are available. Comparative studies to evaluate national pro-
grams supporting employment in people with vision loss, availability
of adaptive technology and societal perceptions of disability would
help to understand which strategies are efficient and effective. A fur-
ther extension could compare productivity losses from vision loss
with those from other impairments and health conditions.
Furthermore, there is a need for more robust data on other com-
ponents of productivity losses we had to omit, such as absenteeism
and presenteeism, productivity losses of caregivers, and time lost
from unpaid or informal labour activities as well as how these are
associated with access and quality of health care. In particular, the
relationship between vision impairment and unpaid labour, both in
terms of its measurement and valuation, is an area that has received
little attention. An increased understanding of this may allow it to be
included in future economic studies. Without the inclusion of all of
these components, estimates will continue to underestimate the
magnitude of productivity losses. Increasing the number of studies
reporting prevalence of vision impairment worldwide will also
reduce uncertainty regarding prevalence and the subsequent produc-
tivity loss estimates. In this domain, prevalence data by country
would allow for more detailed analysis of differences between coun-
tries and regions. Better data on employment status of people with
vision impairment, other productivity loss components and more
detailed prevalence data would provide more reliable information to
analyse change over time and projections into the future that could
aid strategic decision making. Finally, future estimates would benefit
from more robust data for the 6569 year-old age group, particularly
in countries where the retirement age is increasing.
Employment is an important determinant of economic develop-
ment, social inclusion and well-being for individuals, households,
communities and nations. It supports financial independence, pov-
erty reduction, physical and psychological health and quality of life
[2]. Given the benefits of employment, the reduced employment lev-
els amongst people with vision loss needs to be addressed. First,
there are effective treatments for cataract and uncorrected refractive
error, the leading causes of MSVI and blindness. Therefore, increasing
access to treatment for these and other conditions should be a global
priority to increase workforce participation and productivity gains.
Second, for people whose vision cannot be restored, access to vision
rehabilitation care and workplace adaptation should also be provided
to help people with vision loss to stay in the labour market. Third,people in high-income countries, and with higher socioeconomic sta-
tus within all countries, likely have better access to new technologies
and vision aids to enable workforce participation. Solutions must be
found to overcome these persistent inequities while developing and
implementing policies that enable labour force participation by all
who wish to pursue it. These policies could include incentive pro-
grammes to hire and support people with vision impairment, to
adapt workplaces, and to promote equitable access to full and fair
employment, promotion and career development plans. Through the
assurance of fair employment and decent working conditions of peo-
ple with vision loss, governments and the private sector can help
eradicate poverty, alleviate social inequities, improve health, improve
well-being, and increase economic productivity.
Our findings support the view that blindness and MSVI have a
large economic impact worldwide. All world regions need to invest
in increasing access to eye health services to prevent or treat avoid-
able vision loss, and to develop and deliver services and inclusive
environments to enable visually impaired people to find and main-
tain employment. These actions would likely result in significant pro-
ductivity gains.
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